Summary
This prediction ended on 01.11.18 with a price of €13.53. The prediction for Merus BV disappointed with a performance of -16.67%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merus BV | - | - | - | - |
| iShares Core DAX® | -0.372% | 5.236% | 16.908% | 16.016% |
| iShares Nasdaq 100 | -1.950% | 1.680% | 19.890% | 31.832% |
| iShares Nikkei 225® | -1.690% | 7.286% | 12.202% | 3.400% |
| iShares S&P 500 | -0.399% | 2.379% | 20.975% | 36.224% |
Comments by stratec for this prediction
In the thread Merus BV diskutieren
Merus will yield meaningful clinical data in the near future.
A lucrative partnership was signed with Incyte last year for which they received $120 million upfront and a common share purchase of $80 million. Incyte in return received exclusive rights for up to 11 bispecific antibody research programs utilizing Merus' Biclonics technology, which included two preclinical immuno-oncology candidates.
The technology of Merus has the potential to be sufficiently differentiated from monoclonal antibodies due to improved tumor cell killing activity and lower toxicity.
(Laufzeit überschritten)